Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q96S06

UPID:
LMF1_HUMAN

ALTERNATIVE NAMES:
Transmembrane protein 112

ALTERNATIVE UPACC:
Q96S06; B3KS80; Q68CJ3; Q96FJ4; Q9H6G4; Q9H9K7

BACKGROUND:
The protein Lipase maturation factor 1, alternatively known as Transmembrane protein 112, is pivotal in the endoplasmic reticulum for the maturation of specific proteins. It ensures the proper maturation and transport of lipoprotein lipase (LPL) in the secretory pathway, chaperoning more than 50 LPL molecules.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Lipase maturation factor 1 could open doors to potential therapeutic strategies, especially considering its critical function in the development and transport of lipoprotein lipase (LPL), which is vital for lipid metabolism.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.